ASPN

ASPN (PLAP-1/asporin) is an extracellular matrix small leucine-rich repeat proteoglycan that acts as a multi-target regulator of growth factor and inflammatory signaling and as a structural organizer of connective tissue (PMID:17522060, PMID:37958972). It directly binds BMP-2 and inhibits BMP-2-induced cytodifferentiation and mineralization, competitively blocking BMP-2 engagement of BMP receptor-IB and the downstream Smad cascade through its LRR5 motif, which alone is sufficient to recapitulate inhibition (PMID:17522060, PMID:18407830); the N-terminal aspartic acid repeat length tunes this activity, with the D14 variant binding BMP-2 more strongly and suppressing differentiation more potently than D13 (PMID:24453179). In contrast to its inhibitory role toward BMP-2, ASPN positively regulates FGF-2 by binding it and promoting FGF-2–FGFR1 complex formation (PMID:26239644). ASPN also binds TLR2 and TLR4 to dampen NF-κB activation, stabilizing IκBα and reducing proinflammatory cytokine output (PMID:26399972), and it suppresses HIF-1α transcriptional activity in a hypoxia-induced feedback loop (PMID:35138637). Consistent with a matrix-organizing function, ASPN-deficient mice show enlarged periodontal ligament space, altered collagen fibril architecture, and accelerated alveolar bone resorption (PMID:37958972). Across mesenchymal lineages ASPN restrains osteogenic differentiation of periodontal ligament and bone marrow stromal cells while promoting adipogenesis (PMID:33654143, PMID:25038933, PMID:26031659). In cancer, ASPN contributes to oxaliplatin resistance in colorectal cancer and amplifies MATN3-driven gastric cancer progression (PMID:36228517, PMID:39301785).

1. 2007 High

   Established ASPN as a direct binding partner and negative regulator of BMP-2 signaling, defining its first molecular function beyond being a matrix proteoglycan.

   Evidence Co-immunoprecipitation with gain- and loss-of-function in periodontal ligament cells

   PMID:17522060

   Open questions at the time

   • Did not resolve the binding domain or whether inhibition was receptor-competitive
   • Limited to PDL cell context
2. 2008 High

   Resolved the mechanism of BMP-2 inhibition as competitive blockade of BMPR-IB and mapped the activity to the LRR5 motif, converting a binding observation into a defined structure-function model.

   Evidence Recombinant competition binding, LRR5 mutagenesis, and a 26-aa peptide rescue with Smad phosphorylation readout

   PMID:18407830

   Open questions at the time

   • No structural model of the ASPN–BMP-2 interface
   • Relevance in vivo not tested
3. 2014 Medium

   Showed the N-terminal aspartic acid repeat polymorphism tunes ASPN function, linking an allelic variant to differential BMP-2 binding strength and inhibitory potency.

   Evidence D13 vs D14 stable cell lines, Co-IP, reporter and mineralization assays

   PMID:24453179

   Open questions at the time

   • Single-lab Co-IP for affinity difference
   • Molecular basis for repeat-dependent affinity not defined
4. 2014 Medium

   Extended the anti-osteogenic role beyond PDL by showing ASPN inhibits osteoblast differentiation of bone marrow stromal cells.

   Evidence Retroviral overexpression in rBMSCs with osteogenic marker and mineralization assays

   PMID:25038933

   Open questions at the time

   • Gain-of-function only
   • Mechanism downstream of BMP/FGF not separated
5. 2015 High

   Revealed a context-dependent positive regulatory role: ASPN binds FGF-2 and promotes FGF-2–FGFR1 complex formation, contrasting with its BMP-2 inhibition.

   Evidence Plap-1 knockout MEFs with rescue, binding assay, and FGF-2/FGFR1 co-localization

   PMID:26239644

   Open questions at the time

   • How ASPN can be inhibitory for BMP-2 yet stimulatory for FGF-2 mechanistically unresolved
   • Domain mediating FGF-2 binding not mapped
6. 2015 High

   Defined an anti-inflammatory function through direct TLR2/TLR4 binding and suppression of NF-κB signaling.

   Evidence Immunoprecipitation, NF-κB reporter, IκBα western blot, cytokine ELISA in PDL cells and macrophages

   PMID:26399972

   Open questions at the time

   • TLR binding site on ASPN not mapped
   • Whether ASPN acts as TLR antagonist or sequesters ligand unclear
7. 2015 Medium

   Confirmed in vivo relevance of ASPN as an osteogenesis inhibitor in a skeletal repair model.

   Evidence rBMSC overexpression transplanted into rat critical-size skull defects with histology

   PMID:26031659

   Open questions at the time

   • Overexpression model only
   • No loss-of-function comparison
8. 2019 Medium

   Placed ASPN under transcriptional control of vitamin D signaling, identifying a VDRE that links 1,25(OH)2D3 to ASPN suppression and enhanced osteogenesis.

   Evidence ChIP and luciferase reporter assays in hPDLSCs

   PMID:31837573

   Open questions at the time

   • Single-lab regulatory mapping
   • Other transcriptional regulators not addressed
9. 2021 Medium

   Identified a pro-adipogenic function for ASPN, broadening its mesenchymal lineage role beyond bone.

   Evidence Plap-1 knockout mice, siRNA in 3T3-L1, and recombinant protein lipid accumulation assays

   PMID:33654143

   Open questions at the time

   • Signaling pathway driving adipogenesis not defined
   • Relation to BMP/FGF activities unclear
10. 2022 Medium

    Established a hypoxia feedback loop in which HIF-1α induces ASPN, which in turn suppresses HIF-1α transcriptional activity.

    Evidence Hypoxic culture, chetomin inhibition, HRE reporter, and nuclear HIF-1α western blot

    PMID:35138637

    Open questions at the time

    • Mechanism of HIF-1α suppression not defined
    • Limited orthogonal validation
11. 2022 High

    Demonstrated through genetic ablation that ASPN is required for normal periodontal ligament collagen organization and protects against periodontitis-associated bone loss.

    Evidence PLAP-1 KO mice with micro-CT, TEM, histology, tooth extraction force, and ligature-induced periodontitis

    PMID:37958972

    Open questions at the time

    • Molecular link between ASPN and collagen fibrillogenesis not detailed
    • Tissue-specific roles outside PDL untested
12. 2022 Medium

    Implicated ASPN in cancer drug resistance, showing its knockdown reverses oxaliplatin resistance in colorectal cancer.

    Evidence siRNA knockdown with apoptosis assays and patient-derived xenograft model

    PMID:36228517

    Open questions at the time

    • Mechanism of resistance not defined
    • No link to ASPN signaling partners
13. 2023 Medium

    Identified HAPLN1 as an ASPN partner cooperating to inhibit osteogenic differentiation.

    Evidence Co-IP/binding and synergistic siRNA knockdown in BMSCs from OVX mice

    PMID:37427673

    Open questions at the time

    • Interaction interface not mapped
    • Single-lab interaction data
14. 2024 Medium

    Linked ASPN to gastric cancer progression via a MATN3-ASPN interaction amplifying tumor growth and metastasis.

    Evidence Protein-protein interaction analysis with overexpression/knockdown functional assays and in vivo tumor model

    PMID:39301785

    Open questions at the time

    • Downstream signaling of MATN3-ASPN not defined
    • Mechanism of metastatic enhancement unclear
15. 2026 Medium

    Showed ASPN transcription is driven by an exosomal NamiRNA acting on its super-enhancer during H. pylori infection, connecting ASPN to gastric inflammation.

    Evidence miRNA-seq, co-culture, H3K27ac ChIP, and in vivo antagomir treatment

    PMID:41723544

    Open questions at the time

    • Single-lab epigenetic mechanism
    • Direct ASPN protein function in this context not tested

• How ASPN integrates its opposing activities (BMP-2 inhibition versus FGF-2 promotion) at the level of shared structural domains and matrix context, and how these reconcile with its roles in adipogenesis, fibrosis, and cancer, remains unresolved.
• No structural model of ASPN bound to any ligand
• Unclear whether matrix sequestration vs receptor competition predominates across contexts